Home > Insider Trading > Filing (0001562180-23-005321)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1822791	Clene Inc.	CLNN	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1251956	J David Matlin	6550 South Millrock Drive Suite G50 Salt Lake City UT 84121		No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-06-16	1,500,000	$0.80	6,793,684	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Warrants (Right to buy)	Acquisiton	2023-06-16	1,500,000	$0.00	1,500,000	$1.50
Common Stock	Warrants (Right to buy)	Acquisiton	2023-06-16	1,500,000	$0.00	1,500,000	$1.10

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
1,500,000	2023-06-16		No	4	A	Direct
1,500,000	2023-06-16		No	4	A	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	150,000	Indirect	By Trust

Footnotes

The securities are owned by the Matlin Family Trust 2020. Mr. Matlin in the trustee of the Matlin Family Trust 2020. The shares owned by the Matlin Family Trust 2020 may be deemed to be beneficially owned by Mr. Matlin.
The price for each Unit is $0.80; one Unit consists of one share of Common Stock of Clene, one Tranche A Warrant and one Tranche B Warrant.
The reporting person purchased a unit consisting of one share of Common Stock of Clene Inc., one Tranche A Warrant, and one Tranche B Warrant. The Tranche B Warrant is for 1,500,000 shares of Common Stock of Clene Inc. at an exercise price of $1.50 per share. The Tranche B Warrant will expire on the earlier of (a) June 16, 2030, or (b) 60 days after the Food and Drug Administration accepts a New Drug Application from Clene Inc.
The reporting person purchased a unit consisting of one share of Common Stock of Clene Inc., one Tranche A Warrant, and one Tranche B Warrant. The Tranche A Warrant is for 1,500,000 shares of Common Stock of Clene Inc. at an exercise price of $1.10 per share. The Tranche A Warrant will expire on the earlier of (a) June 16, 2026, or (b) 60 days after the Food and Drug Administration accepts a New Drug Application from Clene Inc.